Management of burning mouth syndrome: systematic review and management recommendations

Patton, Lauren L.; Siegel, M.; Benoliel, Raphael; Laat, Antoon De

doi:10.1016/j.tripleo.2006.11.009

Cited by 180 publications

(242 citation statements)

References 53 publications

Supporting

Mentioning

217

Contrasting

Unclassified

Order By: Relevance

“…236,237 Topical clonazepam has been used in the management of neuropathic oral conditions and anecdotal data in taste and smell complaints have been published. 238,239 Topical application, while relatively benign, may be a problem for patients with little or no saliva. Using a clonazepam solution may be acceptable but has not been tested.…”

Section: Managementmentioning

confidence: 99%

Oral complications of cancer and cancer therapy

Epstein

Thariat

Bensadoun

et al. 2012

CA A Cancer J Clinicians

412

356

View full text Add to dashboard Cite

Answer questions and earn CME/CNEOral complications resulting from cancer and cancer therapies cause acute and late toxicities that may be underreported, underrecognized, and undertreated. Recent advances in cancer treatment have led to changes in the incidence, nature, and severity of oral complications. As the number of survivors increases, it is becoming increasingly recognized that the aggressive management of oral toxicities is needed to ensure optimal long‐term oral health and general well‐being. Advances in care have had an impact on previously recognized oral complications and are leading to newly recognized adverse effects. Here, the authors briefly review advances in cancer therapy, including recent advances in surgery, oral care, radiation therapy, hematopoietic cell transplantation, and medical oncology; describe how these advances affect oral health; and discuss the frequent and/or severe oral health complications associated with cancer and cancer treatment and their effect upon long‐term health. Although some of the acute oral toxicities of cancer therapies may be reduced, they remain essentially unavoidable. The significant impact of long‐term complications requires increased awareness and recognition to promote prevention and appropriate intervention. It is therefore important for the primary oncologist to be aware of these complications so that appropriate measures can be implemented in a timely manner. Prevention and management is best provided via multidisciplinary health care teams, which must be integrated and communicate effectively in order to provide the best patient care in a coordinated manner at the appropriate time. CA Cancer J Clin 2012. © 2012 American Cancer Society.

show abstract

Section: Managementmentioning

confidence: 99%

Oral complications of cancer and cancer therapy

Epstein

Thariat

Bensadoun

et al. 2012

CA A Cancer J Clinicians

412

356

View full text Add to dashboard Cite

show abstract

“…In addition, all patients used several drugs to treat systemic chronic diseases, which impair the diagnosis of primary BMS. The observations in this study show that the current definition of BMS may need to be revised due to the great difficulty in classifying the patient in the strict clinical criteria stablished, also evidenced by other researchers 3,21,22 .…”

Section: Discussionmentioning

confidence: 61%

Clinical characteristics and therapeutic response in patients with Burning Mouth Syndrome: accompanying 2 years

Carvalho

Gallo

Sugaya

et al. 2017

Rev. odontol. UNESP

View full text Add to dashboard Cite

ResumoIntrodução: A Síndrome de Ardência Bucal (SAB) é uma condição caracterizada pelo sintoma de ardência na mucosa oral na ausência de qualquer sinal clínico. Sua etiologia ainda é desconhecida e, até o momento, não dispõe de tratamento efetivo. Objetivo: Avaliar o perfil do paciente portador de SAB, as terapias instituídas e seus resultados em estudo retrospectivo. Material e método: Foram coletados os dados clínicos e terapêuticos dos prontuários de pacientes diagnosticados com SAB, no período de janeiro de 2013 a abril de 2015, no Ambulatório da Disciplina de Estomatologia Clínica da Faculdade de Odontologia da Universidade de São Paulo. Os critérios para o diagnóstico utilizados se basearam nos estabelecidos pela International Headache Society em 2013 e foram observadas as terapêuticas empregadas e seus resultados. Resultado: Doze pacientes foram diagnosticadas com SAB neste período, todas do sexo feminino, média de idade 61,18 anos, e a principal região acometida pelo sintoma de ardor foi o ápice de língua. O tempo de duração deste sintoma variou de 6 meses a 25 anos. As terapias utilizadas para o controle de sintomas da SAB foram capsaicina, clonazepan tópico, laserterapia e homeopatia. Dentre as terapias instituídas, a capsaicina apresentou efeito imediato na redução dos sintomas. Conclusão: O presente estudo demonstrou que os desafios que circundam a obtenção de um tratamento efetivo para a SAB são diversos e estão principalmente relacionados ao desconhecimento da etiopatogenia da doença. O perfil demográfico dos pacientes aqui estudados foi semelhante ao descrito na literatura disponível, entretanto, as variáveis representadas por sintomas secundários (história médica, níveis de ansiedade e depressão) podem constituir fatores modificadores da resposta terapêutica e da própria etiopatogenia da doença. Descritores: Síndrome da Ardência Bucal; tratamento; dor neuropática AbstractIntroduction: Burning Mouth Syndrome (BMS) is a condition characterized by burning symptom of the oral mucosa in the absence of clinical signs. Its etiology is still unknown and, and to date there is no effective treatment. Purpose: The aim of this study was to evaluate patients with BMS profile and the therapies results in a retrospective study. Material and method: Clinical and therapeutic data were collected from records of patients with BMS diagnosed between January 2013 to April 2015 at the Clinic of Stomatology Clinic, Faculdade de Odontologia of Universidade de São Paulo, according to the criteria established by the International Headache Society in 2013. The therapies used for BMS control were also evaluated. Result: Twelve patients were diagnosed with BMS at this period. All of them were women with a mean age of 61.18 years and the apex of the tongue was the most common affected site and the duration of the burning sensation ranged from 6 months to 25 years. Many therapies were prescribed for BMS control, such as topical capsaicin, topical clonazepan, low level laser therapy and homeopathy. Among the established therapie...

show abstract

“…These differences between genders may be explained by biological, psychological & sociocultural factors. Prevalences of BMS reported from international studies ranges from 0.7%-4.5% 11,[14][15][16][17][18] . Epidemiological studies revealed that this condition is more common in pre and postmenopausal women which ranges upto 12-18% 19 .…”

Section: Discussionmentioning

confidence: 99%

“…Xerostomia may be the complaints of approximately 46-67% of BMS patient 6,8,11 . Other symptoms include dysgeusia, sensory disturbance and sticky sensation, dysphagia, burning irritation of lingual papilla, pruritis, and intolerance to prosthesis 14,17 . Oral findings are erythema, geographic tongue, candidiasis, atrophic glossitis, lichen planus 49 .…”

Section: Clinical Featuresmentioning

confidence: 99%

Burning Mouth Syndrome: A Review

Sadat

Chowdhury

Baten³

2017

J. Bangladesh Coll. Phys.

View full text Add to dashboard Cite

Burning Mouth Syndrome (BMS) is characterized by chronic oro-facial pain in the absence of specific oral lesions & clinically apparent mucosal alterations. It is more commonly observed in middle aged patients & postmenopausal women. It often affects tongue, cheek, lip, hard & soft palate. Usually symptoms are better observed in morning, worsen during the day and typically subside at night. The condition is multifactorial origin, often idiopathic and its etiopathogenesis remain largely enigmatic. Associated medical conditions may include neurologic and metabolic disorder, gastrointestinal, urogenital as well as drug reactions. BMS are of two types, primary & secondary. Primary BMS is essential or idiopathic where secondary BMS is caused by local, systemic and/or psychological factors. Clinical diagnosis depends on the careful history taking, physical examinations and laboratory findings. Vitamin, Zinc or Hormone replacement therapy has been found to be effective with deficiency of the corresponding factors. The drug therapy with alpha-lipoic acid, capsaicin, clonazepam, benzodiazepines, tricyclic antidepressants, anticonvulsants may be effective in symptomatic treatment of BMS. But the treatment is still unsatisfactory and there is no definitive cure.J Bangladesh Coll Phys Surg 2016; 34(3): 151-159

show abstract

Management of burning mouth syndrome: systematic review and management recommendations

Cited by 180 publications

References 53 publications

Oral complications of cancer and cancer therapy

Oral complications of cancer and cancer therapy

Clinical characteristics and therapeutic response in patients with Burning Mouth Syndrome: accompanying 2 years

Burning Mouth Syndrome: A Review

Contact Info

Product

Resources

About